TECH Signal 413
VA Launches Psilocybin Trial Comparing Two Dosage Levels for Veterans with Treatment-Resistant Depression and PTSD
↗
The U.S. Department of Veterans Affairs has initiated a randomized, controlled clinical trial evaluating psilocybin's effectiveness and safety for veterans with treatment-resistant major depressive disorder, including those with concurrent PTSD.
This trial represents a significant federal investment in psychedelic therapy research for a population with limited treatment options. The study's design comparing two dosage levels could yield actionable clinical data on dose-response relationships critical for therapeutic protocols.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
The randomized, controlled trial will compare outcomes between two psilocybin dosage levels for veterans with treatment-resistant major depressive disorder, with or without concurrent PTSD.
The trial follows a recent executive order on 'Accelerating Medical Treatments for Serious Mental Illness' aimed at increasing clinical trial participation and accelerating psychedelic drug approvals.
The VA is currently involved in 20 active clinical trials focused on psychedelic therapies for mental health conditions, all conducted under strict safety protocols and federal guidelines.
THE CLUSTER